PDCD1 and neoplasm: In particular, TXNIP depletion could be of interest in combination with immunotherapies (such as anti-PD-1 or other immune checkpoint blockers) to boost T cell immunity and/or for the development of next-generation CAR-T cells by improving their anti-tumor efficacy.